# OnCo record gemstone-302 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/gemstone-302/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "gemstone-302", "NCT03789604" ;
  schema:name "GEMSTONE-302"@en ;
  schema:description "The trial behind sugemalimab's approval in China and later Europe, showing a PD-L1 antibody plus chemotherapy delays progression in both main types of lung cancer."@en ;
  schema:url <https://onco.cc/trials/gemstone-302/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03789604>, <https://doi.org/10.1016/S1470-2045(21)00650-1> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "3" ;
  schema:startDate "2018-12-13" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/sugemalimab/> ;
  onco:companies <https://onco.cc/companies/cstone/> ;
  onco:people <https://onco.cc/people/zhou-caicun/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gemstone-302-lancet-oncol-2022/>, <https://onco.cc/key-papers/paper-gemstone-302-nat-cancer-2023-update/> .